Screening and Identification of Marburg Virus Entry Inhibitors Using Approved Drugs

• 来源期刊: 中国病毒学
• 年，卷（期）: 2020,（2）
• 页码范围: 235-239
• 页数: 5页
• 语种: 英文

摘要

Dear Editor,Marburg virus (MARV) belongs to the Filoviridae family,along with the related Ebola virus (EBOV).Although MARV is less renowned than EBOV,it causes an equally devastating disease,with clinical symptoms similar to EBOV infection and a remarkably high mortality rate.To date,about 600 MARV cases have been reported globally,with an average mortality rate of around 80％ (Brauburger et al.2012).Due to the severity of disease caused by MARV,as well as its threat to global public health,MARV is classified as a risk group 4 pathogen by WHO,neces-sitating containment measures equivalent to biosafety level 4 (BSL-4).Moreover,MARV is considered a potential agent of bioterrorism (Leffel and Reed 2004) and,since 2015,has been listed as one of ten priority pathogens on WHO's Blueprint of Priority.However,drug development specific for MARV is seldomly reported,although some studies for drugs against EBOV have identified compounds that may also be effective against MARV (Madrid et al.2013;Bixler et al.2017;Cross et al.2018).MARV is a single-stranded negative-sense RNA virus.